Unamatatizo ya nguvu za tumia dawa hii

[nachid]

dah! bahati mbaya sina namna ya kukuwajibisha lakini ulichofanya si sahihi hata kidogo, dawa huwa hazitangazwi hovyo kama wewe ulivyoandika na ndio maana hata ukisikiliza vipindi vya redio madaktari huzungumza ugonjwa, dalili, vipimo lakini itakapokuja dawa hawataitaja maana dawa na dose ziko individualized, aina utakayotumia wewe siyo nitakayotumia mimi, hali kadhalika dosi utakayotumia wewe siyo nitakayotumia mimi, maana japokuwa twaweza kuwa na tatizo moja lakini mwili wako ni tofauti na mwili wangu hali kadhalika severity of disease kwako ni tofauti na kwangu, sasa wewe hapo unapopromote hiyo dawa kisha mtu akaenda akajinywea hovyo akifa au akipata madhara itakuwaje?

social media ni nzuri lakini uncontrolled medical promotion and advertising ni mbaya sana, kwanza ni kinyume cha sheria kutangaza dawa kwenye vyombo vya habari ndio maana hujawahi kusikia dawa yoyote ikitangazwa gazetini au kwenye redio au tv, with exception of ALU, na hii ALU ilifanywa makusudi ili wananchi waielewe maana wengi walikuwa wakiikataa na pia ilifanywa kwa kuwa malaria ni disease of national interest na sio tatizo 'dogo' kitaifa kama impotence

pili hapo umefanya makosa mawili kwanza kutangaza tadalafil lakini mbaya zaidi unaitangaza LEVITRA kwamba ndio tadalafil lakini levitra ni VARDENAFIL, mimi ningekuwa ni mods ningeiondoa hii thread kwa sababu umefanya pharmaceutical advertising kinyemela kwa kuitangaza specifically LEVITRA, je wewe ndo agent wake hapa bongo? lakini pia umechanganya watu kwa kuwaambia levitra ndio tadalafil wakati levitra ni vardenafil

jamani tusipende kutumia madawa hovyo kwa kusoma kwenye internet, kusoma kutoka kwa watu laymen kama hawa bila kwenda hospitalini, ni hatari sana, especially hizi dawa za mitindo ya maisha, life style diseases sio nzuri kujinywea hovyo hovyo, na mwisho dawa za kuongeza nguvu za kiume ni HATARI sana kama una matatizo  katika mfumo wako wa damu( cardiovascular system).

thanks ndo raha ya jf

 

[uporoto01]

Dozi ni kidonge kimoja kwa wiki na bei inarange kati ya elfu nane na kumi kwa kidonge

Mkuu hii Levitra yenye jina la Sahiil inauzwa 4500/- na ni kweli haina kuumwa kichwa au moyo kwenda mbio na haiathiriwi na kilevi.Hawa wanaosema kuhusu eti usitumie dawa bila ya ushauri wa daktari achana nao hayajawakuta.Madaktari wetu sio ndio hawa wanaodai mtu ana malaria 200 ? au mgonjwa wa goti anapasuliwa kichwa ? au mgonjwa wa kichomi anapigwa sindano za malaria ?

 

[King2]

piga msosi vizuri, mlo kamili na safi. Pata kitimoto rost na bia mbili jioni. Jenga afya vizuri. Ndo dawa ya nguvu mkuu. Hayo machemical yawe kimbilio la mwisho.

umeongea jambo la maana mkuu. Ila bia nayo inaua.. Matunda, vegetable, pork ni mzuka kurudisha heshima.

 

[Gosbertgoodluck]

Dawa ya nguvu za kiume na kula vyakula asili na balanced full stop.

 

[Bujibuji Simba Nyamaume]

mi nguvu zimenizidia, yaani hata nikiwapanga ishirini hawanipunguzi hamu, naombeni dawa tafadhali

 

[Eddy Love]

Supu ya pweza na konyagi ndo mpango mzima try now ujionee

 

[Herbalist Dr MziziMkavu]

Side effects

Tadalafil has been used in approximately 15,000 men participating in clinical trials, and over 8 million men worldwide (primarily in the post-approval/post-marketing setting). The most common side effects when using tadalafil are headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition to vasodilate (cause blood vessels to widen) and usually go away after a few hours. Back pain and muscle aches can occur 12 to 24 hours after taking the drug, and the symptom usually disappears after 48 hours.

In May 2005, the U.S. Food and Drug Administration found that tadalafil (along with other PDE5 inhibitors) was associated with vision impairment related to NAION (nonarteritic anterior ischemic optic neuropathy) in certain patients taking these drugs in the post-marketing (outside of clinical trials) setting. Most, but not all, of these patients had underlying anatomic or vascular risk factors for development of

NAION unrelated to PDE5 use, including: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. Given the small number of NAION events with PDE5 use (less than 1 in 1 million), the large number of users of PDE5 inhibitors (millions) and the fact that this event occurs in a similar population to those who do not take these medicines,

the FDA concluded that they were not able to draw a cause and effect relationship, given these patients underlying vascular risk factors or anatomical defects. However, the label of all three PDE5 inhibitors was changed to alert clinicians to a possible association.
In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, including tadalafil, requires a more prominent warning of the potential risk of sudden hearing loss as the result of postmarketing reports of deafness associated with use of PDE5 inhibitors.[SUP][7][/SUP]

 

[frisky]

natafuta viara